W3 Series S11 · Intended / Planned · AGI Future Foundation
Molecular.
Molecular. is W3 Series S11, a planned series whose name points to molecular science and biotechnology. It is intended, not formed, funded, or offered.
A note on how thin this page is: very little is verified about this series beyond its name and its place in the April 2026 internal W3 series list. This page says so plainly rather than filling the gap with invented detail. The description below is limited to the domain the name implies, labelled as a planned focus throughout — what the series would aim at if formed, not what it does today. No users, customers, partners, revenue, sites, timelines, or results are claimed, because none are verified.
What this series is
Molecular. is W3 Series S11 in the Foundation's intended W3 network. Its name is the only verified detail about it beyond its number and its place in the April 2026 internal W3 series list. This page therefore describes it only as a planned series whose focus, as the name implies, would be molecular science: molecules, molecular data, and the biotechnology and research work built around them. That is a description of a domain, not a claim that any laboratory, dataset, product, trial, or research result exists today under this name.
The planned focus deserves a careful statement, because molecular work spans very different kinds of activity, and no choice among them is recorded. It could in principle mean computational work with molecular structures and data; laboratory research; diagnostics or therapeutics development; or tools and infrastructure for other researchers. Each is a different undertaking with different regulation, safety obligations, partners, and timelines, and this page does not pick one on the series' behalf. The planned focus is stated at the level of the domain itself: molecular science and biotechnology, pursued by agents under human governance, if the series is ever formed.
The boundaries for a series in this domain are unusually important, and they should be stated before any plan is described. Molecular and biotech work can touch human health, safety, and the environment, and it is governed by regulation that does not bend for a new corporate form. Nothing on this page claims a treatment, a diagnostic, a cure, a trial result, or a regulatory approval for this series. Any future laboratory, clinical, or diagnostic work would need qualified human leadership, institutional review where required, regulatory counsel, and safety review before it began — and agents would not design, approve, or run such work on their own authority. A series that handled molecular data would also need a data-governance design from the start: where data comes from, what consent covers, how it is stored and shared, and how errors are corrected.
It is also worth recording what this page does not have. No molecule files, datasets, or research records for this series were found in the files reviewed, and no consolidation of such records is claimed here. The Foundation's wider work has included a search for molecule files across the workspace, uploads, and documents, and that search did not produce files that could be attributed to this series. If molecular records are later supplied, they should be consolidated locally and cited with their source — and only then should this page describe any specific molecule, dataset, or result.
The questions a future steward would need to answer are therefore foundational: what exactly would Molecular. do, and what would it refuse to do? Would it build computational tools, run laboratory research, support other researchers, or pursue a specific application — and which application, under whose qualified leadership, and under which regulator? What safety and ethics review would every project pass through, and who would have the power to stop one? What data would it hold, and under what consent? None of those questions has a verified answer today. Listing them is a record of the work that remains before this planned series could become a real one, not a substitute for doing it.
The filing facts that anchor this page are narrow, and they are worth stating before any description of the series itself. AGI Future Foundation is a California Nonprofit Public Benefit Corporation, Entity No. B20260196664, with Articles filed on 2026-04-24. Its Employer Identification Number was assigned on 2026-05-07. No IRS 501(c)(3) determination letter is in the files reviewed for this site, so this page does not claim that the Foundation is tax-exempt, and it does not claim that any donation to the Foundation is tax-deductible. Nothing on this page is legal, tax, or financial advice.
The same discipline applies to the series itself. Being named in an internal list is not the same as being formed. A Wyoming series LLC designation, a bank account, an employer identification number for the series, a signed operating agreement, a cap table, a customer, or a dollar of revenue would each be a separate, verifiable fact. None of those facts is claimed for this series on this page, because none of them is verified in the filings reviewed. If a future filing changes that, this page should be updated to cite the document, the date, and the issuing authority — not merely to change the wording.
Metaverse connection
There is no anchored metaverse fabric yet for this series. No coordinates, no fabric JSON, no hosted 3D assets, and no RP1 attach are claimed for this series, because none is verified. Nothing in this section should be read as a world that exists, a location that has been chosen, or a virtual space a reader can visit today.
What would be needed before this series could honestly claim a metaverse connection is a short, concrete list, and none of it exists yet for this series. First, an anchor: a named place with published coordinates that the series has actually chosen, not a coordinate invented to make a page look finished. Second, a fabric: a fabric JSON file describing that world, published where it can be checked. Third, hosted assets: the 3D models and supporting files the world needs, actually hosted and reachable, so the world renders instead of failing to load. Fourth, an RP1 attach: a verified step that brings the world into RP1, confirmed by a live check rather than asserted on a page. Until all four exist, the correct statement is the one at the top of this section: no anchored metaverse fabric yet.
That standard is stated here because the Foundation's metaverse work elsewhere shows how easy it is to overclaim. A fabric file can be live on a public host while the assets it points to are not, and a world can be described in detail while rendering only partly — or not at all — in a viewer. This page therefore treats a metaverse connection as a verifiable chain (coordinates, fabric, hosted assets, live render, RP1 attach), and it reports this series as having none of that chain yet. If the series later gains an anchor, this section should be updated with the coordinates, the fabric link, the asset hosting, and the date and result of the live render check — each as a dated, checkable fact. In the meantime, the planned metaverse role for a series like this one is best described as a question for its future stewards, not as a feature: would a virtual space help the people this series would serve, and if so, what would it need to contain to be useful rather than decorative? No such decision is recorded here, because no such decision has been made.
What exists today vs. what is planned
What exists today
- The series name and number, as listed in the April 2026 internal W3 series list (an internal printout, not a Wyoming filing).
- The Foundation's own filing record, cited on this page: California Nonprofit Public Benefit Corporation, Entity No. B20260196664, filed 2026-04-24, EIN assigned 2026-05-07.
- This page itself: a public, honest description of a planned series, with its status stated up front.
That is the complete list. There is no formed series company, no designation document, no bank account, no EIN for this series, no operating agreement, no signed customer or partner agreement, no site, no product, and no money raised that this page can verify.
What is planned
The plan, as far as it can honestly be stated today, is to keep this series as a named, planned focus until qualified human leadership, with counsel, decides whether it should be formed at all — and if so, what exactly it would do and under what oversight.
- Decide, in writing, whether Molecular. should be formed, and if so, which part of molecular science it would serve and which parts it would explicitly refuse.
- Appoint qualified human scientific and safety leadership before any laboratory, clinical, or diagnostic work is considered, and define the ethics and safety review every project must pass.
- Commission a data-governance design for any molecular or personal data the series would hold, including source, consent, storage, sharing, and correction.
- Choose a governance form — series designation, operating agreement, and Steward Council appointments — with counsel, if formation is approved.
- Only then, decide whether a metaverse presence would serve the series' researchers or users, and build it to the four-part standard described in the metaverse section above.
Each step would need its own document, decision, and, where required, counsel's review. None is presented here as done, scheduled, or promised by a date, because no date is verified.
How it fits
Tier. This series is intended to sit in the commercial tier of the Foundation's planned three-tier structure: the Foundation as the governance and mission tier; the W3 LLC series network as the commercial engine; and each named series, including this one, as one specialised cell inside that network. That tiering is a plan, not a current legal fact, because the W3 LLC formation and this series' designation are not verified in filings. The Foundation is the only filed entity in that chain this page can cite, and it is a California nonprofit public benefit corporation — not a for-profit parent, not an owner of a formed series, and not a guarantor of any series' future.
Related series. The nearest neighbours in the numbering are Series S10 (SmartCiti.X) and Series S12 (ParkingSmart.X), and the wider group on this site runs from S09 through S16. Numbering proximity is the only relationship this page claims: the series in this group share a place in the same internal list and the same intended W3 structure, and no operational partnership, shared customer, shared product, shared dataset, or shared funding between this series and any other series is claimed. The Foundation's wider biotech funding research is a separate research exercise, not a Molecular. programme, and no grant, application, or award is claimed for this series.
Governance for this series, as planned, follows the model used across the intended W3 network. Day-to-day work would be DAO-managed: agents would operate the routine work of the series within limits set in advance by humans. Humans decide, humans sign, and humans move funds. Agents do not sign documents, do not move money, do not hire or fire, do not offer securities, and do not enact doctrine or charters. A human Steward Council would hold the decision authority, set the limits inside which agents may act, review what agents did, and remain accountable for the result. That separation is deliberate: the point of an agent-managed series is not to remove human responsibility, but to make routine work faster while keeping consequential decisions in human hands.
That governance model is itself planned, not yet operating for this series. There is no Steward Council roster, no operating agreement, and no published set of agent limits for this series to point to today. Naming the intended model here is a statement of intent about how the series would be run if it were formed — it is not evidence that the model is already running. The Foundation's role in the intended structure is as mission steward, under written mission agreements, with its board remaining independent: a California nonprofit cannot be owned or controlled by a for-profit head, so control would run only through those written agreements, designed with counsel.
Three practical consequences follow. First, no agent message, draft, or page like this one is a commitment by the series or the Foundation; only a named human acting within signed, written authority can commit either one. Second, any future fundraising, partnership, or customer agreement for this series would need its own legal documents, its own issuer, and counsel review — the series name alone authorises nothing. Third, the public record for this series should grow only as real documents are created: a designation, an operating agreement, a council appointment, a signed agreement. Until then, the honest public record is this page's status banner.
Proposed projects — for DAO review
These are proposals for the series DAO team to review. None is approved, funded, staffed, or scheduled.
The name is the only verified detail about this series beyond its number and its place in the April 2026 internal W3 series list. The name implies molecular science: molecules, molecular data, and the biotechnology and research work built around them. The proposals below are generic to that name-implied planned focus, and no laboratory, dataset, product, trial, or research result is verified under this name.
Scope paper
A one-page written statement of what molecular science means for this series: molecules, molecular data, and the research work built around them, with boundaries stated. The paper would be approved by stewards before any research begins. No such paper exists today.
What success would look like: A scope paper exists that the stewards have approved, stating what molecular work means here.
Reviewing team: the Molecular DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Molecular data stewardship proposal
A proposal for how molecular data would be held, shared, and protected, including who may access it and for what purposes. The proposal would be written before any dataset is collected. No dataset is verified for this series.
What success would look like: A stewardship proposal exists naming who may access molecular data and under what terms.
Reviewing team: the Molecular DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Research question catalogue
A catalogue of research questions this series might pursue, written so stewards can judge which questions are worth asking and which are out of scope. The catalogue would be a planning document, not a claim of results. No research is verified for this series.
What success would look like: A catalogue exists with research questions and a note on why each one matters.
Reviewing team: the Molecular DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Safety and dual-use review note
A written note on how this series would review molecular work that could be misused, including who reviews it and what stops a risky line of work. The note would be approved before any research starts. No such note exists today.
What success would look like: A review note exists describing who reviews risky work and what can stop it.
Reviewing team: the Molecular DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Separation note with S18 BioDAO
A written note clarifying that S11 Molecular stays separate from S18 BioDAO.blockchain DAO, while noting that the Biotech tool repo is titled biodao.blockchain and its content is a molecular workspace. The note would keep the two series distinct and flag the overlap for the DAO teams. No such note exists today.
What success would look like: A separation note exists that both DAO teams have read, keeping S11 and S18 distinct while flagging the overlap.
Reviewing team: the Molecular DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Code and repositories
No dedicated repository for this series exists in the Foundation account — a name search over all 90 public repositories, checked 2026-11-06/07, found none; the S18 overlap (the AGI-Biotech-tool molecular workspace and the ALS Researcher site) is described in “The biology in depth” below and is not claimed for this series. Two generated agent files touch it, neither read in full in this pass. In agi-corp-worlds, agents/prompts/s11-molecular.json is one of the roughly 40 generated prompt files from the metaprompt system, and its spec metaprompt is marked not ready in the prompt index: the founder focus for this series is unset, labelled “awaiting a founder focus” and never filled with a guess. In WorldForge-Browser, a per-series tutor prompt, worldforge/out/training/tutors/s11-molecular.md, was identified in the org sweep; its contents have not been read, so nothing about it is described here. An Omega liaison card for this series is listed in the s04–s35 range of the 38 agent cards in Metropolis-SmartCiti (agents/cards/); its contents were not individually read. See the organisation on GitHub: AGIFutureFoundation.
Visit in VR
There is no flagship 3D world for Molecular, and no playable world exists for this series yet. What exists is an index listing: the series appears as a curated entry (s11-molecular) in the worlds-3d 544-world index, and a series directory (worlds/s11-molecular/) exists in agi-corp-worlds. Its founder focus is unset in that repo’s focus sheet — labelled “awaiting a founder focus”, never filled with a guess — and its spec metaprompt is marked not ready in the prompt index.
- Foundation VR tour — the Foundation’s VR tour shell.
- worlds-3d lobby — the seven flagship worlds and the full 544-world index, where this series is listed.
Zero worlds are live on RP1, and the lobby labels itself a web 3D interpretation — not RP1, not footage. A world for this series becomes real only when a steward writes its focus into the focus sheet.
The biology in depth

Molecular medicine works at the level of molecules: proteins, genes, and the small compounds that bind them. A disease is traced to a molecular mechanism — a protein folded wrong, a gene switched on at the wrong time, a signalling pathway stuck open — and a therapy is designed to act on that mechanism. The everyday tools of the field are target identification, structural biology, compound screening, docking (predicting how a small molecule fits a protein), and molecular dynamics (simulating how molecules move over time). Docking scores rank candidates; they do not measure binding affinity, and a ranked list is the start of experimental work, not its conclusion.
Longevity research is partly molecular: ageing is studied through molecular damage, repair pathways, and gene regulation. That is a research direction with open questions, not a set of established interventions. This page claims no longevity outcome or therapy, because none is verified for this series.
What is verified for this series is an overlap, not a dedicated repository. No dedicated repository for S11 Molecular exists in the Foundation account — a name search over all 90 public repositories, checked 2026-11-06/07, found none. Two real artifacts overlap this series from S18. The first is AGI-Biotech-tool, a local molecular workspace for drug discovery titled biodao.blockchain: docking plus OpenMM dynamics, 60 targets verified against UniProt, 21 public databases listed as sources, and hash-chained provenance. Its own README states its limits plainly: docking scores are a Vina re-implementation for ranking, not affinity; its redock benchmark passes 2 of 4 cases; values marked [SYNTHETIC] are placeholders, not measurements; a BigQuery panel has not been run end to end; and nothing it produces is a clinical, diagnostic, or dosing recommendation. Its licence is Proprietary — no right to use, copy, modify, or distribute without a separate written agreement. The second is the ALS Researcher agent site at als.agifuturefoundation.org, live and returning 200, described as developing a synthetic compound library; its six listed Virtuals ACP jobs and one subscription are priced on the BioDAO tools page. The two series stay separate: the tool is cited under S18 by its title, and the overlap is flagged here, not resolved by merging.
Planned work for this series — a written mission naming the molecular fields in scope, a Steward Council, and any laboratory or computational work under qualified human direction with ethics review and counsel — is described in the sections above as planned, not existing. No trial, result, partnership, or timeline is verified for S11 Molecular.
All verified BioDAO tools are listed together, with charts, on the BioDAO tools page.
Get involved / contact
If this planned series interests you, the route is a conversation, not a transaction. Write to [email protected] and say who you are, what you do, and what you would like to explore — research, a future partnership, volunteering, or a question about the Foundation's mission. A human steward will read it. Please do not send money, do not ask for investment terms, and do not treat this page as an invitation to invest: there is no offering here, no price, no terms, and no return is promised or implied.
What is genuinely useful at this stage is specific, verifiable help: a named contact in the field the series would serve, a written source that corrects or confirms something on this page, a question that exposes a gap in the plan, or an offer to review a draft document. General expressions of interest are welcome, but they do not create a relationship, a membership, or an obligation on either side. The Foundation's contact address above is the only contact route this page offers for this series, and no other person is named here as a contact, a founder, a director, or a partner for this series, because no such appointment is verified.
Nothing on this page is legal, tax, or financial advice, and no signing, membership, payment, investment, or offering is made here. This series is intended/planned, not formed, funded, or offered. The Foundation is a California Nonprofit Public Benefit Corporation, Entity No. B20260196664, filed 2026-04-24; no IRS 501(c)(3) determination letter is in the files reviewed, so no tax-exempt status or tax-deductible donation is claimed.